利用电子临床数据追踪SARS-CoV-2相关脓毒症的发生率与死亡率
这项回顾性队列研究纳入2020年3月至2022年11月马萨诸塞州5家医院的431017例成人住院记录,使用电子健康记录(EHR)客观标准定义SARS-CoV-2相关脓毒症(SARS-CoV-2 PCR阳性+器官功能障碍)和推测细菌性脓毒症(改良CDC成人脓毒症事件标准)。结果显示SARS-CoV-2相关脓毒症占住院的1.5%,占脓毒症的约1/6;其粗住院死亡率从第一季度的33.4%降至最后一季度的14.9%(aOR 0.88/季度),而推测细菌性脓毒症死亡率为14.5%且保持稳定(aOR 1.00)。EHR标准与脓毒症-3标准相比敏感度90.6%、特异度91.2%。研究表明EHR算法可用于病毒性和细菌性脓毒症的监测。
要点
- SARS-CoV-2相关脓毒症占住院的1.5%(6558/431017),约占脓毒症病例的1/6。
- SARS-CoV-2相关脓毒症粗住院死亡率从第一季度的33.4%(490/1469)降至最后一季度的14.9%(67/450),aOR 0.88(95%CI 0.85-0.90)每季度。
- 推测细菌性脓毒症粗死亡率为14.5%(4451/30604),各季度稳定,aOR 1.00(95%CI 0.99-1.01)。
- EHR-based SARS-CoV-2相关脓毒症标准与脓毒症-3标准相比,敏感度90.6%(95%CI 80.7%-96.5%),特异度91.2%(95%CI 85.1%-95.4%)。
- SARS-CoV-2相关脓毒症定义:SARS-CoV-2 PCR阳性+并发器官功能障碍(需要超过简单鼻导管氧疗、血管升压药、乳酸升高、肌酐或胆红素升高和/或血小板下降)。
适用人群与场景
- 2020年3月至2022年11月在马萨诸塞州5家医院住院的成人患者。
诊断标准与关键阈值
- SARS-CoV-2相关脓毒症:SARS-CoV-2聚合酶链反应(PCR)检测阳性,并同时存在器官功能障碍(即需要超过简单鼻导管的氧疗支持、使用血管升压药、乳酸水平升高、肌酐或胆红素水平升高和/或血小板下降)。
- 推测细菌性脓毒症:采用改良美国疾病控制与预防中心(CDC)成人脓毒症事件标准(即血培养医嘱、持续抗生素治疗,以及使用与SARS-CoV-2相关脓毒症相同的阈值定义的器官功能障碍)。
研究设计与关键结果
- 研究类型:回顾性队列研究,纳入5家马萨诸塞州医院的431017例住院记录(来自261595名个体;平均[SD]年龄57.9[19.8]岁;女性241131例[55.9%];学术医院站点286397例[66.5%])。
- 暴露:SARS-CoV-2相关脓毒症6558例(1.5%),推测细菌性脓毒症(无SARS-CoV-2感染)30604例(7.1%),SARS-CoV-2住院23276例(5.4%)。
- 主要结局:SARS-CoV-2相关脓毒症粗住院死亡率从第一季度的33.4%(490/1469)降至最后一季度的14.9%(67/450),调整比值比(aOR)为0.88(95%CI 0.85-0.90)每季度。
- 推测细菌性脓毒症粗死亡率为14.5%(4451/30604),各季度稳定(aOR 1.00,95%CI 0.99-1.01)。
- 对200例SARS-CoV-2阳性住院记录进行病历审查,确认基于电子健康记录(EHR)的SARS-CoV-2相关脓毒症标准相对于脓毒症-3标准表现良好:敏感度90.6%(95%CI 80.7%-96.5%),特异度91.2%(95%CI 85.1%-95.4%)。
- 结论:在COVID-19大流行前33个月,SARS-CoV-2约占脓毒症病例的1/6;SARS-CoV-2相关脓毒症住院死亡率高但随时间下降,最终与推测细菌性脓毒症相似。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 基于EHR的算法可用于病毒性和细菌性脓毒症的监测,作者认为这展示了EHR算法在脓毒症监测中的效用。
- SARS-CoV-2相关脓毒症住院死亡率随时间下降,最终与推测细菌性脓毒症相似,提示临床关注其高负担。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Efforts to quantify the burden of SARS-CoV-2-associated sepsis have been limited by inconsistent definitions and underrecognition of viral sepsis.
OBJECTIVE: To describe the incidence and outcomes of SARS-CoV-2-associated sepsis vs presumed bacterial sepsis using objective electronic clinical criteria.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included adults hospitalized at 5 Massachusetts hospitals between March 2020 and November 2022.
EXPOSURES: SARS-CoV-2-associated sepsis was defined as a positive SARS-CoV-2 polymerase chain reaction test and concurrent organ dysfunction (ie, oxygen support above simple nasal cannula, vasopressors, elevated lactate level, rise in creatine or bilirubin level, and/or decline in platelets). Presumed bacterial sepsis was defined by modified US Centers for Disease Control and Prevention adult sepsis event criteria (ie, blood culture order, sustained treatment with antibiotics, and organ dysfunction using identical thresholds as for SARS-CoV-2-associated sepsis).
MAIN OUTCOMES AND MEASURES: Trends in the quarterly incidence (ie, proportion of hospitalizations) and in-hospital mortality for SARS-CoV-2-associated and presumed bacterial sepsis were assessed using negative binomial and logistic regression models.
RESULTS: This study included 431 017 hospital encounters from 261 595 individuals (mean [SD] age 57.9 [19.8] years, 241 131 (55.9%) females, 286 397 [66.5%] from academic hospital site). Of these encounters, 23 276 (5.4%) were from SARS-CoV-2, 6558 (1.5%) had SARS-CoV-2-associated sepsis, and 30 604 patients (7.1%) had presumed bacterial sepsis without SARS-CoV-2 infection. Crude in-hospital mortality for SARS-CoV-2-associated sepsis declined from 490 of 1469 (33.4%) in the first quarter to 67 of 450 (14.9%) in the last (adjusted odds ratio [aOR], 0.88 [95% CI, 0.85-0.90] per quarter). Crude mortality for presumed bacterial sepsis was 4451 of 30 604 patients (14.5%) and stable across quarters (aOR, 1.00 [95% CI, 0.99-1.01]). Medical record reviews of 200 SARS-CoV-2-positive hospitalizations confirmed electronic health record (EHR)-based SARS-CoV-2-associated sepsis criteria performed well relative to sepsis-3 criteria (90.6% [95% CI, 80.7%-96.5%] sensitivity; 91.2% [95% CI, 85.1%-95.4%] specificity).
CONCLUSIONS AND RELEVANCE: In this retrospective cohort study of hospitalized adults, SARS-CoV-2 accounted for approximately 1 in 6 cases of sepsis during the first 33 months of the COVID-19 pandemic. In-hospital mortality rates for SARS-CoV-2-associated sepsis were high but declined over time and ultimately were similar to presumed bacterial sepsis. These findings highlight the high burden of SARS-CoV-2-associated sepsis and demonstrate the utility of EHR-based algorithms to conduct surveillance for viral and bacterial sepsis.
参考来源
- Shappell CN, Klompas M, Chan C, et al. Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2-Associated Sepsis. JAMA Netw Open. 2023. PMID: 37773495. doi:10.1001/jamanetworkopen.2023.35728
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。